Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0095-91 55513-0095 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0096-01 55513-0096 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0096-91 55513-0096 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0097-01 55513-0097 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0097-91 55513-0097 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0098-01 55513-0098 Darbepoetin alfa Aranesp 10.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Oct. 6, 2015 In Use
55513-0098-04 55513-0098 Darbepoetin alfa Aranesp 10.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 26, 2006 In Use
55513-0110-01 55513-0110 Darbepoetin alfa Aranesp 300.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 14, 2006 In Use
55513-0111-01 55513-0111 Darbepoetin alfa Aranesp 300.0 ug/.6mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 14, 2006 In Use
55513-0126-01 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0126-10 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0132-01 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 11, 2019 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0144-01 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0144-10 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-01 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec. 18, 2014 In Use
55513-0164-01 55513-0164 Traztuzumab-anns, trastuzumab-anns Kanjinti Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 1, 2023 In Use
55513-0190-01 55513-0190 Pegfilgrastim Neulasta 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous April 1, 2002 In Use
55513-0192-01 55513-0192 Pegfilgrastim Neulasta Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Feb. 20, 2015 In Use
55513-0206-01 55513-0206 Bevacizumab-awwb MVASI 100.0 mg/4mL, 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use

Found 10,000 results in 9 milliseconds — Export these results